Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + epirubicin + cyclophosphamide (Bristol Myers Squibb)
- Development stage
- Phase 4
- Lead developer
- Fudan University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a neoadjuvant chemotherapy regimen consisting of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) followed by a dose-intensive combination of epirubicin and cyclophosphamide (EC). It is specifically being evaluated by Fudan University for the treatment of triple-negative breast cancer (TNBC). Nab-paclitaxel is a microtubule inhibitor that stabilizes tubulin, preventing the depolymerization necessary for cell division. Epirubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks. Cyclophosphamide is an alkylating agent that forms cross-links with DNA, interfering with replication and transcription. The regimen is designed to improve pathological complete response (pCR) rates in patients with early-stage or locally advanced TNBC by sequencing a taxane with an anthracycline-based combination.
- Other names
- Nab-P followed by ECNab-P + ECNanoparticle Albumin-Bound Paclitaxel + Epirubicin + Cyclophosphamide
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + epirubicin + cyclophosphamide (Bristol Myers Squibb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + epirubicin + cyclophosphamide (Bristol Myers Squibb).